Upcoming Dividend • Jun 26
Upcoming dividend of ₹11.00 per share Eligible shareholders must have bought the stock before 03 July 2026. Payment date: 09 August 2026. Payout ratio is a comfortable 21% but the company is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.8%). Reported Earnings • Jun 20
Full year 2026 earnings: EPS and revenues miss analyst expectations Full year 2026 results: EPS: ₹51.60 (up from ₹48.62 in FY 2025). Revenue: ₹14.2b (up 2.0% from FY 2025). Net income: ₹1.67b (up 6.1% from FY 2025). Profit margin: 12% (in line with FY 2025). Revenue missed analyst estimates by 4.8%. Earnings per share (EPS) also missed analyst estimates by 4.3%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Price Target Changed • Jun 17
Price target increased by 7.6% to ₹1,414 Up from ₹1,314, the current price target is an average from 2 analysts. New target price is 34% below last closing price of ₹2,152. Stock is up 49% over the past year. The company is forecast to post earnings per share of ₹43.20 for next year compared to ₹51.60 last year. Announcement • Jun 09
Balaji Amines Limited, Annual General Meeting, Jul 10, 2026 Balaji Amines Limited, Annual General Meeting, Jul 10, 2026, at 12:00 Indian Standard Time. Valuation Update With 7 Day Price Move • Jun 05
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹2,043, the stock trades at a trailing P/E ratio of 39.6x. Average forward P/E is 28x in the Chemicals industry in India. Total loss to shareholders of 3.8% over the past three years. Board Change • Jun 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 4 highly experienced directors. Independent Director Suhasini Shah was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • May 26
New major risk - Revenue and earnings growth Earnings have declined by 18% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 18% per year over the past 5 years. High level of non-cash earnings (28% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (9.5% average weekly change). Valuation Update With 7 Day Price Move • May 20
Investor sentiment improves as stock rises 36% After last week's 36% share price gain to ₹1,833, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 29x in the Chemicals industry in India. Total loss to shareholders of 14% over the past three years. Reported Earnings • May 15
Full year 2026 earnings: EPS and revenues miss analyst expectations Full year 2026 results: EPS: ₹51.60 (up from ₹48.62 in FY 2025). Revenue: ₹14.5b (up 4.1% from FY 2025). Net income: ₹1.67b (up 6.1% from FY 2025). Profit margin: 12% (in line with FY 2025). Revenue missed analyst estimates by 4.8%. Earnings per share (EPS) also missed analyst estimates by 4.3%. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. New Risk • May 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.9% average weekly change). Valuation Update With 7 Day Price Move • May 06
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹1,492, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 30x in the Chemicals industry in India. Total loss to shareholders of 36% over the past three years. Announcement • May 04
Balaji Amines Limited to Report Q4, 2026 Results on May 13, 2026 Balaji Amines Limited announced that they will report Q4, 2026 results on May 13, 2026 Reported Earnings • Feb 01
Third quarter 2026 earnings released: EPS: ₹9.49 (vs ₹10.24 in 3Q 2025) Third quarter 2026 results: EPS: ₹9.49 (down from ₹10.24 in 3Q 2025). Revenue: ₹3.31b (up 5.9% from 3Q 2025). Net income: ₹314.3m (down 5.3% from 3Q 2025). Profit margin: 9.5% (down from 11% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings. New Risk • Jan 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (20% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (6.9% average weekly change). Announcement • Jan 19
Balaji Amines Limited to Report Q3, 2026 Results on Jan 29, 2026 Balaji Amines Limited announced that they will report Q3, 2026 results on Jan 29, 2026 Valuation Update With 7 Day Price Move • Jan 14
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹1,265, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 27x in the Chemicals industry in India. Total loss to shareholders of 47% over the past three years. Price Target Changed • Nov 15
Price target decreased by 7.5% to ₹1,709 Down from ₹1,847, the current price target is an average from 3 analysts. New target price is 39% above last closing price of ₹1,229. Stock is down 40% over the past year. The company is forecast to post earnings per share of ₹63.56 for next year compared to ₹48.62 last year. Reported Earnings • Nov 11
Second quarter 2026 earnings released: EPS: ₹10.67 (vs ₹12.65 in 2Q 2025) Second quarter 2026 results: EPS: ₹10.67 (down from ₹12.65 in 2Q 2025). Revenue: ₹3.48b (flat on 2Q 2025). Net income: ₹345.6m (down 16% from 2Q 2025). Profit margin: 9.9% (down from 12% in 2Q 2025). Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings. Announcement • Nov 03
Balaji Amines Limited to Report Q2, 2026 Results on Nov 10, 2025 Balaji Amines Limited announced that they will report Q2, 2026 results at 12:15 PM, Indian Standard Time on Nov 10, 2025 Upcoming Dividend • Jul 25
Upcoming dividend of ₹11.00 per share Eligible shareholders must have bought the stock before 01 August 2025. Payment date: 07 September 2025. Payout ratio is a comfortable 23% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of Indian dividend payers (1.2%). In line with average of industry peers (0.7%). Announcement • Jul 24
Balaji Amines Limited to Report Q1, 2026 Results on Aug 02, 2025 Balaji Amines Limited announced that they will report Q1, 2026 results at 3:30 PM, Indian Standard Time on Aug 02, 2025 Reported Earnings • Jul 16
Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2025 results: EPS: ₹48.62 (down from ₹63.22 in FY 2024). Revenue: ₹14.0b (down 15% from FY 2024). Net income: ₹1.58b (down 23% from FY 2024). Profit margin: 11% (down from 13% in FY 2024). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 2.8%. Earnings per share (EPS) exceeded analyst estimates by 7.3%. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings. Announcement • Jul 10
Balaji Amines Limited, Annual General Meeting, Aug 08, 2025 Balaji Amines Limited, Annual General Meeting, Aug 08, 2025, at 12:00 Indian Standard Time. Price Target Changed • Jul 01
Price target increased by 20% to ₹1,972 Up from ₹1,640, the current price target is an average from 2 analysts. New target price is 8.0% above last closing price of ₹1,825. Stock is down 25% over the past year. The company is forecast to post earnings per share of ₹63.56 for next year compared to ₹48.62 last year. Valuation Update With 7 Day Price Move • Jun 25
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹1,673, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 31x in the Chemicals industry in India. Total loss to shareholders of 41% over the past three years. Reported Earnings • May 29
Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2025 results: EPS: ₹48.62 (down from ₹63.22 in FY 2024). Revenue: ₹14.3b (down 13% from FY 2024). Net income: ₹1.58b (down 23% from FY 2024). Profit margin: 11% (down from 13% in FY 2024). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 2.8%. Earnings per share (EPS) exceeded analyst estimates by 7.3%. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings. Announcement • May 28
Balaji Amines Limited Recommends Final Dividend Balaji Amines Limited at its board of directors meeting held on May 28, 2025, recommended a final dividend of INR 11.00 per equity share i.e. 550% on face value of INR 2.00 per share and the same will be payable after it is approved by the shareholders at the 37th Annual General Meeting of the Company. Announcement • May 18
Balaji Amines Limited to Report Q4, 2025 Results on May 26, 2025 Balaji Amines Limited announced that they will report Q4, 2025 results on May 26, 2025 Buy Or Sell Opportunity • May 16
Now 21% overvalued Over the last 90 days, the stock has fallen 2.1% to ₹1,404. The fair value is estimated to be ₹1,163, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 18% over the last 3 years. Earnings per share has declined by 29%. Revenue is forecast to grow by 26% in 2 years. Earnings are forecast to grow by 71% in the next 2 years. Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹1,312, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 28x in the Chemicals industry in India. Total loss to shareholders of 58% over the past three years. Valuation Update With 7 Day Price Move • Mar 24
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹1,358, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 28x in the Chemicals industry in India. Total loss to shareholders of 52% over the past three years. Buy Or Sell Opportunity • Feb 19
Now 23% overvalued Over the last 90 days, the stock has fallen 30% to ₹1,395. The fair value is estimated to be ₹1,130, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 18% over the last 3 years. Earnings per share has declined by 29%. Revenue is forecast to grow by 26% in 2 years. Earnings are forecast to grow by 71% in the next 2 years. Reported Earnings • Feb 13
Third quarter 2025 earnings released: EPS: ₹10.24 (vs ₹15.24 in 3Q 2024) Third quarter 2025 results: EPS: ₹10.24 (down from ₹15.24 in 3Q 2024). Revenue: ₹3.21b (down 16% from 3Q 2024). Net income: ₹331.9m (down 33% from 3Q 2024). Profit margin: 10% (down from 13% in 3Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings. Announcement • Feb 05
Balaji Amines Limited to Report Q3, 2025 Results on Feb 12, 2025 Balaji Amines Limited announced that they will report Q3, 2025 results on Feb 12, 2025 Buy Or Sell Opportunity • Jan 30
Now 21% overvalued Over the last 90 days, the stock has fallen 22% to ₹1,683. The fair value is estimated to be ₹1,385, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last 3 years. Earnings per share has declined by 25%. Revenue is forecast to grow by 42% in 2 years. Earnings are forecast to grow by 96% in the next 2 years. Price Target Changed • Nov 20
Price target decreased by 12% to ₹2,328 Down from ₹2,648, the current price target is provided by 1 analyst. New target price is 17% above last closing price of ₹1,996. Stock is down 1.7% over the past year. The company is forecast to post earnings per share of ₹54.20 for next year compared to ₹63.22 last year. Reported Earnings • Nov 16
Second quarter 2025 earnings released: EPS: ₹12.65 (vs ₹10.71 in 2Q 2024) Second quarter 2025 results: EPS: ₹12.65 (up from ₹10.71 in 2Q 2024). Revenue: ₹3.56b (down 6.4% from 2Q 2024). Net income: ₹409.8m (up 18% from 2Q 2024). Profit margin: 12% (up from 9.1% in 2Q 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Announcement • Nov 14
Balaji Amines Limited Announces Company Secretary Changes Balaji Amines Limited announced that at the board meeting held on November 14, 2024, approved the resignation of Mr. Lakhan S. Dargad as Company Secretary of the Company with effect from closing of business hours on December 30, 2024. Appointment of Mr. Abhijeet S. Kothadiya as a Company Secretary of the Company with effect from December 31, 2024. Mr. Abhijeet S. Kothadiya is an Associate Member of the Institute of Company Secretaries of India having Membership No. 68288 having good amount of experience in corporate and allied laws. Announcement • Nov 06
Balaji Amines Limited to Report Q2, 2025 Results on Nov 14, 2024 Balaji Amines Limited announced that they will report Q2, 2025 results on Nov 14, 2024 Reported Earnings • Aug 08
First quarter 2025 earnings released: EPS: ₹13.36 (vs ₹16.28 in 1Q 2024) First quarter 2025 results: EPS: ₹13.36 (down from ₹16.28 in 1Q 2024). Revenue: ₹3.93b (down 15% from 1Q 2024). Net income: ₹432.9m (down 18% from 1Q 2024). Profit margin: 11% (in line with 1Q 2024). Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Announcement • Jul 26
Balaji Amines Limited to Report Q1, 2025 Results on Aug 07, 2024 Balaji Amines Limited announced that they will report Q1, 2025 results on Aug 07, 2024 Reported Earnings • Jun 23
Full year 2024 earnings: EPS exceeds analyst expectations Full year 2024 results: EPS: ₹63.22 (down from ₹100 in FY 2023). Revenue: ₹16.4b (down 30% from FY 2023). Net income: ₹2.05b (down 37% from FY 2023). Profit margin: 13% (down from 14% in FY 2023). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.2%. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Announcement • Jun 19
Balaji Amines Limited, Annual General Meeting, Jul 11, 2024 Balaji Amines Limited, Annual General Meeting, Jul 11, 2024, at 12:00 Indian Standard Time. Declared Dividend • Jun 19
Dividend increased to ₹11.00 Dividend of ₹11.00 is 10% higher than last year. Ex-date: 4th July 2024 Payment date: 10th August 2024 Dividend yield will be 0.5%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (17% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 30% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 74% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • May 09
Full year 2024 earnings: EPS exceeds analyst expectations Full year 2024 results: EPS: ₹63.22 (down from ₹100 in FY 2023). Revenue: ₹16.7b (down 29% from FY 2023). Net income: ₹2.05b (down 37% from FY 2023). Profit margin: 12% (down from 14% in FY 2023). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.2%. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Announcement • May 09
Balaji Amines Limited Recommends Final Dividend, for the Year Ended 31 March, 2024 Balaji Amines Limited at the Board of Directors Meeting held on 8 May, 2024 recommended a final dividend of INR 11 per equity share 550% on face value of INR 2 per share, for the year ended 31 March, 2024 and the same will be payable after it is approved by the shareholders at the 36 Annual General Meeting of the Company. Announcement • May 03
Balaji Amines Limited to Report Q4, 2024 Results on May 08, 2024 Balaji Amines Limited announced that they will report Q4, 2024 results on May 08, 2024 Reported Earnings • Feb 01
Third quarter 2024 earnings released: EPS: ₹15.24 (vs ₹19.31 in 3Q 2023) Third quarter 2024 results: EPS: ₹15.24 (down from ₹19.31 in 3Q 2023). Revenue: ₹3.92b (down 33% from 3Q 2023). Net income: ₹493.7m (down 21% from 3Q 2023). Profit margin: 13% (up from 11% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings. Announcement • Jan 24
Balaji Amines Limited to Report Q3, 2024 Results on Jan 31, 2024 Balaji Amines Limited announced that they will report Q3, 2024 results on Jan 31, 2024 Valuation Update With 7 Day Price Move • Dec 27
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹2,670, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 188% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹1,718 per share. Valuation Update With 7 Day Price Move • Dec 07
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹2,347, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 159% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹1,738 per share. Price Target Changed • Nov 22
Price target decreased by 16% to ₹2,768 Down from ₹3,278, the current price target is an average from 2 analysts. New target price is 36% above last closing price of ₹2,030. Stock is down 30% over the past year. The company is forecast to post earnings per share of ₹125 for next year compared to ₹100 last year. Reported Earnings • Nov 09
Second quarter 2024 earnings released: EPS: ₹10.71 (vs ₹28.57 in 2Q 2023) Second quarter 2024 results: EPS: ₹10.71 (down from ₹28.57 in 2Q 2023). Revenue: ₹3.87b (down 39% from 2Q 2023). Net income: ₹347.1m (down 63% from 2Q 2023). Profit margin: 9.0% (down from 15% in 2Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Nov 03
Balaji Amines Limited to Report Q2, 2024 Results on Nov 08, 2023 Balaji Amines Limited announced that they will report Q2, 2024 results on Nov 08, 2023 Reported Earnings • Sep 01
First quarter 2024 earnings released: EPS: ₹16.28 (vs ₹37.95 in 1Q 2023) First quarter 2024 results: EPS: ₹16.28 (down from ₹37.95 in 1Q 2023). Revenue: ₹4.69b (down 31% from 1Q 2023). Net income: ₹527.3m (down 57% from 1Q 2023). Profit margin: 11% (down from 18% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Aug 22
Balaji Amines Limited to Report Q1, 2024 Results on Aug 31, 2023 Balaji Amines Limited announced that they will report Q1, 2024 results on Aug 31, 2023 Announcement • Jul 13
Balaji Amines Limited Approves Dividend for the Financial Year 2022-23 Balaji Amines Limited at its AGM held on July 10, 2023, approved dividend of INR 10 per equity share for the financial Year 2022-23. Upcoming Dividend • Jun 26
Upcoming dividend of ₹10.00 per share at 0.4% yield Eligible shareholders must have bought the stock before 03 July 2023. Payment date: 09 August 2023. Payout ratio is a comfortable 10.0% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.9%). Reported Earnings • Jun 24
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2023 results: EPS: ₹100 (down from ₹114 in FY 2022). Revenue: ₹23.6b (up 1.4% from FY 2022). Net income: ₹3.26b (down 12% from FY 2022). Profit margin: 14% (down from 16% in FY 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 7.6%. Earnings per share (EPS) missed analyst estimates by 29%. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has increased by 63% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jun 17
Balaji Amines Limited, Annual General Meeting, Jul 10, 2023 Balaji Amines Limited, Annual General Meeting, Jul 10, 2023, at 16:00 Indian Standard Time. Reported Earnings • May 25
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2023 results: EPS: ₹100 (down from ₹114 in FY 2022). Revenue: ₹23.7b (up 2.0% from FY 2022). Net income: ₹3.26b (down 12% from FY 2022). Profit margin: 14% (down from 16% in FY 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 7.6%. Earnings per share (EPS) missed analyst estimates by 29%. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has increased by 74% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 14
Balaji Amines Limited to Report Q4, 2023 Results on May 20, 2023 Balaji Amines Limited announced that they will report Q4, 2023 results on May 20, 2023 Valuation Update With 7 Day Price Move • Apr 12
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹2,486, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 685% over the past three years. Price Target Changed • Apr 05
Price target decreased by 14% to ₹3,790 Down from ₹4,428, the current price target is provided by 1 analyst. New target price is 78% above last closing price of ₹2,128. Stock is down 38% over the past year. The company is forecast to post earnings per share of ₹142 for next year compared to ₹114 last year. Recent Insider Transactions • Mar 22
MD & Whole Time Director recently bought ₹202k worth of stock On the 16th of March, Dundurapu Reddy bought around 100 shares on-market at roughly ₹2,019 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₹1.0m. Dundurapu has been a buyer over the last 12 months, purchasing a net total of ₹419k worth in shares. Recent Insider Transactions • Feb 22
Joint MD & Whole-time Director recently bought ₹244k worth of stock On the 16th of February, Nomula Reddy bought around 98.0 shares on-market at roughly ₹2,494 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₹1.0m. This was Nomula's only on-market trade for the last 12 months. Recent Insider Transactions • Feb 14
Executive Chairman recently bought ₹1.0m worth of stock On the 10th of February, Ande Reddy bought around 480 shares on-market at roughly ₹2,166 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Ande's only on-market trade for the last 12 months.